Vor Bio To Participate in Upcoming September Conferences
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the following investor conferences:
- Wells Fargo 21st Annual Healthcare Conference
Forum: Fireside Chat and 1×1 Meetings
Date: Tuesday, September 8th
Presentation Time: 8:00AM ET
- Citi’s 2026 Biopharma Back to School Conference
Forum: Fireside Chat and 1×1 Meetings
Date: Wednesday, September 9th
Presentation Time: 11:20AM ET
- Morgan Stanley 24th Annual Global Healthcare Conference
Forum: 1×1 Meetings
Date: Monday, September 14th
- Baird’s 2026 Global Healthcare Conference
Forum: Presentation and 1×1 Meetings
Date: Tuesday, September 15th
Presentation Time: 9:05AM ET
- Stifel’s 2026 Virtual Immunology and Inflammation Forum
Forum: Presentation and 1×1 Meetings
Date: Wednesday, September 23rd
Presentation Time: 11:30AM ET
A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be available on the Vor website for approximately 30 days following the presentation.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. Vor Bio routinely posts information that may be important to investors in the “Investors” section of its website. The Company encourages investors to consult that section of its website regularly.
Media & Investor Contacts: Carl Mauch cmauch@vorbio.com
